|
The FDA on Nov. 16 granted Eli Lilly’s Rezvoglar, a biosimilar to Sanofi’s insulin
Lantus, interchangeability with its reference product. This approval marks
the second interchangeable copy of Lantus — Viatris and Biocon Biologics’
Semglee hit the market in November 2021. For the treatment of type 2
diabetes, Semglee currently holds covered or better status for 60% of all
insured lives, to Lantus’ 71%. |
|
SOURCE: MMIT Analytics,
as of 11/21/22 |
No comments:
Post a Comment